Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis
Open Access
- 13 October 2022
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (10) , e0275888
Abstract
Background: Clinical benefit of paclitaxel-coated devices for patients with peripheral arterial disease has been confirmed in randomized controlled trials (RCTs). A meta-analysis published in 2018 identified late mortality risk over a long follow-up period due to use of paclitaxel-coated devices in the femoropopliteal arteries, which caused enormous controversy and debates globally. This study aims to further evaluate the safety of paclitaxel-coated devices by incorporating the most recently published data. Methods: We searched for candidate studies in PubMed (MEDLINE), Scopus, EMBASE (Ovid) online databases, government web archives and international cardiovascular conferences. Safety endpoints of interest included all-cause mortality rates at one, two and five years and the risk ratio (RR) was used as the summary measure. The primary analysis was performed using random-effects models to account for potential clinical heterogeneity. Findings: Thirty-nine RCTs including 9164 patients were identified. At one year, the random-effects model yielded a pooled RR of 1.06 (95% CI [0.87, 1.29]) indicating no difference in short-term all-cause deaths between the paclitaxel and control groups (crude mortality, 4.3%, 214/5025 versus 4.5%, 177/3965). Two-year mortality was reported in 26 RCTs with 382 deaths out of 3788 patients (10.1%) in the paclitaxel arm and 299 out of 2955 patients (10.1%) in the control arm and no association was found between increased risk of death and usage of paclitaxel-coated devices (RR 1.08, 95% CI [0.93, 1.25]). Eight RCTs recorded all-cause deaths up to five years and a pooled RR of 1.18 (95% CI [0.92, 1.51]) demonstrated no late mortality risk due to use of paclitaxel-coated devices (crude mortality, paclitaxel 18.2%, 247/1360 versus control 15.2%, 122/805). Conclusions: We found no significant difference in either short- or long-term all-cause mortalities between patients receiving paclitaxel-coated and uncoated devices. Further research on the longer-term safety of paclitaxel usage (e.g., 8- or 10-year) is warranted. Registration: PROSPERO, CRD42021246291.Keywords
Funding Information
- the Research Grants Council of Hong Kong (17308420)
This publication has 77 references indexed in Scilit:
- Drug-Eluting Balloon in Peripheral Intervention for the Superficial Femoral ArteryJACC: Cardiovascular Interventions, 2013
- Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal LesionsJACC, 2013
- Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal AngioplastyCirculation: Cardiovascular Interventions, 2012
- Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidanceBMJ, 2012
- Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial DiseaseCirculation: Cardiovascular Interventions, 2012
- Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal DiseaseCirculation: Cardiovascular Interventions, 2011
- Critical limb ischemiaJournal of Vascular Surgery, 2010
- Inhibition of Restenosis in Femoropopliteal ArteriesCirculation, 2008
- Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trialsEuropean Heart Journal, 2008
- Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the LegNew England Journal of Medicine, 2008